Type 2 Diabetes

For decades, metformin has been the backbone of type 2 diabetes therapy. As we move through 2026, the future of metformin in type 2 diabetes treatment is under fresh scrutiny. Should it still be the first-line agent, or have newer drug classes like GLP‑1 receptor agonists and SGLT2 inhibitors earned …

Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) have transformed type 2 diabetes management by improving blood sugar control and promoting weight loss. Yet as clinical use grows, so does interest in how GLP‑1 medications affect skeletal health — particularly their impact on bone density, remodeling, and fracture risk. This article unpacks …

Asthma is a chronic inflammatory disease of the airways that affects millions worldwide and often overlaps with metabolic conditions such as obesity and type 2 diabetes. Recently, interest has grown in whether glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs)—a class of drugs commonly used to manage diabetes and obesity—could help reduce …

Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction–associated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide. Traditionally, clinicians have associated MASLD with obesity, insulin resistance, and type 2 diabetes, often using body mass index (BMI) and A1C as screening triggers. However, an important shift is occurring …

The updated ADA 2026 standards represent a major shift in how clinicians approach diabetes management. Rather than focusing solely on lowering A1C, these new recommendations promote a broader, holistic strategy that integrates cardiovascular, kidney, and metabolic (CKM) risk management into everyday care. This article breaks down the key updates and …

In recent years, GLP‑1-based treatments for obesity have evolved from being primarily a diabetes-focused strategy to becoming a powerful tool for managing weight and reducing cardiometabolic risk—especially in individuals without type 2 diabetes. This growing trend is shifting how clinicians identify and manage obesity, moving beyond A1C levels to a …

The potential link between GLP‑1 therapies and depression has sparked growing interest among clinicians and researchers. If you’ve ever wondered whether glucagon‑like peptide‑1 (GLP‑1) receptor agonists could positively influence mood, you’re not alone. Early research suggests these medications may ease depressive symptoms by dampening inflammation and influencing brain signaling, though …

Could a diabetes medication help women with PCOS regain control of their cycles and metabolism? GLP‑1 receptor agonists, best known for treating type 2 diabetes and obesity, are showing promise for women with polycystic ovary syndrome (PCOS). These medications may support weight loss, improve insulin resistance, and even lead to …

As GLP‑1 therapies expand into pediatric care, a growing number of providers are asking how to best implement them in adolescents diagnosed with both type 2 diabetes and obesity. The conversation around GLP‑1 therapy for adolescents with type 2 diabetes is evolving quickly. With promising clinical results, these therapies bring …

The GLP‑1 GIP co‑agonist pipeline is ushering in a new era of metabolic therapy that could reshape the way clinicians approach type 2 diabetes and obesity management. As drug developers push beyond single-pathway therapies like GLP‑1 receptor agonists, new combinations—such as GLP‑1/GIP dual agonists and triple agonists—are showing potential to …